CoLucid Pharma has new chief; Biotech center in Wisconsin faces construction woes;

@FierceBiotech: Dendreon, cancer drug developers top slate of buyout candidates. Article | Follow @FierceBiotech

> Aslan Pharmaceuticals has secured a license of Array BioPharma's gastric cancer drug, ARRY-543, a Her2/EGFR inhibitor. Array will financially back the treatment through proof-of-concept, and Aslan will search for partners for commercialization after Phase II testing. The deal could include work on a second compound. Story

> While placebos didn't improve patients' lung function in a recent study, they did make patients feel better. All 39 asthma patients received placebo treatment, an albuterol inhaler and fake acupuncture three times each, and reported greater symptom relief than was documented medically. Item

> There's trouble brewing for a new Madison, WI, biotech center. According to Madison.com, the Madison Development Corp. has to cover a $1.5 million to $2.5 million gap in construction costs, or it could lose a $4.5 million federal grant. And that would jeopardize the entire operation. More

> Fraunhofer USA has established a new six-year partnership to the University of Delaware. The collaboration will provide additional technology and expertise to both the University and Fraunhofer, according to Fraunhofer president Georg Rosenfeld. Report

> CoLucid Pharmaceuticals has appointed Thomas P. Mathers as its new CEO. Release

> Piramal Life Sciences has entered the second stage of its drug discovery partnership with India's Department of Biotechnology. The company hopes to find 14,000 bioactive cultures as it works with nine different national institutes in India. The treatments could be used on a variety of diseases ranging from cancer to inflammation to diabetes. News

Pharma News

@FiercePharma: Expect more pharma M&A, less pharma hiring. Report | Follow @FiercePharma

> How will the generics biz cure its blockbuster hangover? Piece

> Medicis shares drop on death at CEO's house. Item

And Finally... A team at the Harvard Medical School has cracked the genetic code of E. Coli, showing that they can take control of a genome rather than simply copying it, team leaders Farren Isaacs and George Church tell New York Times' Nicholas Wade. More

Suggested Articles

Zentalis is coming out of stealth with an $85 million series C, which will propel its lead programs into pivotal trials and broaden its pipeline.

The planned takeover centers on ARQ 531, a BTK inhibitor that triggered durable responses in patients with B-cell malignancies.

At ASH, Dana-Farber researchers presented promising preclinical data on AMG 701, Amgen's long-lasting BiTE for multiple myeloma, but rivals loom.